To get Mounjaro from your GP, book an appointment to discuss weight management and your eligibility. In England, tirzepatide can be prescribed in primary care as part of a phased NHS rollout, although access depends on local arrangements and whether you fall within the current priority cohort. In Wales and Scotland, access is organised differently, generally through specialist or local weight-management services.
Mounjaro (tirzepatide) is available on the NHS for weight management, but access is limited, phased, and works differently depending on where in the UK you live.
If you are an adult in the UK living with obesity and weight-related health conditions and want to understand whether you can access Mounjaro through the NHS or privately, this guide explains what Mounjaro is, how it works, who is eligible, how the GP and specialist routes work in England, Wales, Scotland and Northern Ireland, likely waiting times, key safety points, and what to do if you do not currently qualify on the NHS.
We are a private pharmacy, so to be upfront: we have an interest here. But the most useful thing we can do is give you the accurate NHS picture first, because access is new, limited and not the same everywhere, and for many people the NHS route is the right place to start.
What Mounjaro Is and What It Does
Mounjaro is the brand name for tirzepatide, a once-weekly injection. It is a weight loss medication that helps people lose weight by acting on two gut-hormone receptors, GIP and GLP-1, which reduce appetite, increase fullness after eating, and slow stomach emptying. It is licensed in the UK both for weight management, alongside healthy eating, physical activity, and other lifestyle changes, and for type 2 diabetes. On the NHS, those are two separate access routes, and this guide focuses mainly on the weight-management route, which is what most people searching are asking about.
Can You Get Mounjaro on the NHS?
Yes, but only for a limited group, and tirzepatide Mounjaro is being rolled out on the NHS in phases. NHS funding for tirzepatide for weight management began in 2025, with access introduced through phased implementation.
NHS England has identified around 220,000 people to receive it for weight management in the first three years, prioritising those with the greatest clinical need, with wider access phased in over 12 years. So the honest position is that eligibility is currently narrow, and meeting the criteria does not by itself guarantee you will be prescribed it.
NHS Eligibility Criteria for Specialist Weight Management Service
Broadly, NHS access for weight management is for adults living with obesity who also have weight-related health conditions. The general criteria are:
- A BMI of 35 or above (a lower threshold may apply for some ethnic groups known to be at higher risk at a lower BMI), and
- One or more weight-related health conditions, such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol or other abnormal blood fats, sleep apnoea, or cardiovascular disease.
NICE sets the broader eligibility criteria, but NHS England is introducing access in phases because of capacity. Current primary-care access is prioritised according to BMI and the number and type of qualifying comorbidities, so meeting the NICE criteria does not necessarily mean you are currently eligible for prescribing through a GP.
There is also a separate route for people with type 2 diabetes, where tirzepatide may be prescribed as a diabetes treatment. That is a different pathway with its own criteria, decided by the team managing your diabetes.
How Access Works in Each UK Nation
This is the part that varies most, and where the keywords people search (Wales, Scotland, "via GP") really matter.
England
In England, tirzepatide is being introduced into primary care through a phased NHS rollout. GP practices and other primary-care models may provide prescribing where local arrangements are in place and the patient falls within the current priority cohort. Tirzepatide is also available through specialist weight-management services. Your route therefore depends on your area, local service arrangements and whether you meet the current phased-access criteria.
Wales
In Wales, access to tirzepatide for weight management is centred on specialist weight-management services. Your GP can assess you and advise whether referral to the appropriate service is suitable.
Scotland
In Scotland, tirzepatide has been accepted for restricted use within NHSScotland. The SMC restriction is generally for adults with a BMI of 30 kg/m² or above and at least one weight-related comorbidity, with lower thresholds potentially appropriate for some ethnic groups. Local health boards determine how services and referral pathways are organised.
Northern Ireland
Provision in Northern Ireland has lagged behind the rest of the UK and arrangements have been developing. Because this is changing, the accurate advice is to check the current local position with your GP or health trust rather than assume it is or is not available.
The Steps to Getting It on the NHS
Wherever you are, the practical route usually looks like this:
- Start by speaking to your GP or the relevant NHS weight-management service in your area. They can explain the local referral and prescribing pathway.
- Assessment. Your GP or another appropriate healthcare professional carries out a clinical review of eligibility, checking your BMI, body weight, weight-related conditions, other medicines, and your documented medical history to see whether treatment is appropriate.
- Prescription or referral. Depending on your nation and practice, your GP either prescribes it (where that route exists and they participate) or refers you to a specialist weight-management service. Tirzepatide is prescribed as part of a wider weight-management approach that includes diet, physical activity and behavioural support where appropriate.
- Specialist service, if referred. These services may involve a healthcare professional alongside programmes that support your weight loss journey, including guidance alongside healthy eating and physical activity advice, and there may be a wait to be seen.
- Ongoing review. Treatment is reviewed by a healthcare professional, and regular monitoring and follow-ups are usually needed while you stay on treatment. Treatment is reviewed regularly. NICE advises that if less than 5% of initial weight has been lost after six months on the highest tolerated dose, the clinician should review the reasons for the response and decide whether continuing treatment is appropriate.
Being Realistic About Waiting Times
Honesty matters here, in both directions. NHS weight-management services can have long waits in some areas, and because the rollout is phased and prioritised, not everyone who is eligible will be seen quickly. That is a genuine limitation worth knowing.
At the same time, it is not a uniformly hopeless picture, waits and provision vary a lot by area, and a participating GP may be able to help sooner than a specialist referral. The best way to find out your realistic timeline is to ask your own GP practice about local provision, rather than relying on a worst-case figure.
A Safety Note Worth Knowing
One practical point the NHS highlights: medications affect contraception in this class.
If you use the oral contraceptive pill, tirzepatide may reduce its effectiveness, so a barrier method such as condoms is advised for four weeks after starting treatment and for four weeks after each dose increase. Speak to your prescriber if you use oral contraception or have questions about other medicines.
Common side effects include nausea, vomiting, diarrhoea and constipation.
Serious adverse effects can occur, including pancreatitis. Low blood sugar is particularly a concern when tirzepatide is used with insulin or sulfonylureas. Seek medical advice if you develop concerning symptoms, and suspected side effects can be reported through the MHRA Yellow Card Scheme.
What If You Do Not Qualify for the NHS Route?
Because NHS criteria are currently narrow, many people who would like Mounjaro for weight management do not yet meet them, or cannot access it quickly where they live. If that is you, the main options are:
- Keep the NHS conversation going. Ask your GP to reassess as the rollout widens, and about local weight-management support you can access now. If Mounjaro is not suitable, you may be offered other regulated options to support weight loss.
- Consider a regulated private option. After assessment by a healthcare professional, a regulated private healthcare provider may issue a private prescription if appropriate. This involves a cost the NHS route does not, but it can be quicker and does not depend on the phased criteria. As a guide, private Mounjaro starts at the 2.5mg dose, and you can see current pricing on our Mounjaro treatment page.
If you do go the private route, it is worth telling your GP, so your care stays joined up. And whichever route you take, the same clinical checks and safety rules apply, a discount or a private option does not remove the need for a proper assessment. You can read more about the wider options on our weight loss treatment hub. EveryDayMeds offers prescription treatments for weight management and other health issues, with medicines sent in discreet packaging.
Key Takeaways
- Mounjaro is on the NHS for weight management, but for a limited, phased group prioritised by clinical need.
- General criteria: body mass index of 35 or above plus one or more weight-related conditions, with lower thresholds that may apply for some groups including South Asian, Black African, Chinese, and Middle Eastern backgrounds.
- England: primary-care prescribing is being phased in, with current access depending on the NHS England priority cohort and local arrangements.
- Wales: specialist weight-management services, via GP referral, not direct GP prescribing.
- Scotland: specialist and local weight-management services, criteria set by each health board.
- Northern Ireland: developing, check the current local position.
- Continuing treatment usually depends on losing at least 5 percent of your starting weight by six months.
- If you do not qualify, a regulated private route is an option, at a cost, through a proper clinical assessment rather than just a purchase, and worth discussing with your GP.
Medical Disclaimer
This article is for general information and educational purposes only and does not constitute medical advice, diagnosis or treatment. Information about Mounjaro (tirzepatide), NHS eligibility and access pathways is based on guidance and information available at the time of publication and may change as recommendations, local NHS arrangements and prescribing policies are updated.
Eligibility for NHS treatment is assessed individually and meeting general criteria does not guarantee that Mounjaro will be prescribed. Speak to your GP, prescriber or relevant NHS weight-management service for advice based on your medical history, current medicines and individual circumstances.
Do not start, stop or change the dose of Mounjaro or any other medicine without advice from a qualified healthcare professional. If you are pregnant, planning a pregnancy, breastfeeding, or have concerns about side effects or other health conditions, seek appropriate medical advice before using or continuing treatment.
If you experience severe or concerning symptoms while taking Mounjaro, seek urgent medical attention.